Notes on Imetelstat

Imetelstat (Rytelo) is indicated for the treatment of adult patients with low- to moderate-risk myelodysplastic syndrome (MDS) and transfusion-dependent anemia who are unresponsive or resistant to erythropoiesis-stimulating agents (ESAs) or who are inappropriate for ESAs. These patients require transfusion of 4 or more units of red blood cells over 8 weeks.

Imetelstat can make you bleed more easily, even from minor injuries. If your bleeding doesn't stop, contact your doctor. Bleeding can also occur inside your body, such as in your stomach, intestines, or brain. You may be more susceptible to infections, even serious or fatal infections. Call your doctor if you develop flu symptoms, cough, night sweats, neck stiffness, confusion, or vision problems.

Before taking this medication, tell your doctor if you have or have had any of the following: easy bruising, unusual bleeding; or an active or chronic infection.

May cause pregnancy problems such as miscarriage or harm an unborn baby. You may need to take a pregnancy test to make sure you are not pregnant. Use effective contraception during imetelstat and for at least 1 week after the last dose. If you are pregnant, tell your doctor.

You may have more difficulty getting pregnant while using imetelstat. You should still use birth control to prevent pregnancy because this medication may harm your unborn baby.

Do not breastfeed while you are using this medicine and for at least 1 week after your last dose

To sum up,Imetelstat (Rytelo) is an innovative drug for patients with specific types of myelodysplastic syndromes. It works by inhibiting telomerase activity and has shown significant therapeutic effects in clinical trials.